Retatrutide and Stomach Pain: Actual Trial Counts and Comparisons
Read the phase 2 abdominal-pain counts by group, with participant-versus-event calculations and the limits of symptom timing claims.
FormBlends Editorial Research · Updated 2026-10-03
Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.
Abdominal pain was reported in the retatrutide phase 2 obesity trial, including in the placebo group. The public registry separates general abdominal pain from upper abdominal pain. That makes it possible to compare the actual participant counts without treating every gastrointestinal event as stomach pain.
How often was abdominal pain reported?
| Registered study group | Abdominal pain | Upper abdominal pain |
|---|---|---|
| Placebo | 2/70 (2.9%) | 2/70 (2.9%) |
| 1 mg LY3437943 | 1/69 (1.4%) | 3/69 (4.3%) |
| 4 mg LY3437943 (2 mg) | 1/33 (3.0%) | 1/33 (3.0%) |
| 4 mg LY3437943 | 0/33 (0.0%) | 0/33 (0.0%) |
| 8 mg LY3437943 (2 mg) | 2/35 (5.7%) | 3/35 (8.6%) |
| 8 mg LY3437943 (4 mg) | 1/35 (2.9%) | 2/35 (5.7%) |
| 12 mg LY3437943 (2 mg) | 2/62 (3.2%) | 3/62 (4.8%) |
Source: NCT04881760 results, non-serious adverse-event terms, checked October 3, 2026. Parentheses in group labels identify starting amounts in the trial. These labels describe study groups, not a personal dosing schedule. The non-serious table uses a 5% reporting threshold for including terms; it is not an exhaustive symptom inventory.
Why a person count differs from an event count
For general abdominal pain, placebo has three recorded events in two of 70 participants. Dividing three by 70 gives 4.3%, but that is not the percentage of participants affected. The participant calculation is two divided by 70, or 2.9%.
In the 8 mg group starting at 2 mg, upper abdominal pain has four recorded events in three of 35 participants. The affected-participant proportion is 8.6%, rather than four divided by 35, or 11.4%. Someone can report more than one event.
The registry does not identify which participants appear in both pain terms. Adding the two term counts would therefore not produce a verified number of unique people with any stomach pain.
What the table can and cannot explain
The table describes reports collected in these study groups. It does not establish the cause of an individual's pain, the time it will start, how long it will last or a treatment response. A placebo report also shows why a symptom recorded during treatment is not automatically attributable to retatrutide.
The observed counts vary across groups and the samples are small. A zero in one row is a recorded count, not proof that a future participant cannot experience the symptom. The whole-table comparison is more informative than choosing only the highest percentage.
Is delayed gastric emptying the same as stomach pain?
A retatrutide gastric-emptying study used acetaminophen blood concentrations as an indirect measurement. That physiological question differs from the pain terms in this registry. It does not identify the cause of every abdominal-pain report.
A practical way to read a symptom claim
- Find the exact event term rather than a broad gastrointestinal label.
- Keep participants affected, total events and the denominator separate.
- Compare the corresponding placebo row.
- Check the reporting threshold and follow-up.
- Look for symptom onset, duration or treatment data before claiming a recovery timeline.
Frequently asked questions
Does the trial show abdominal pain can occur?
Yes. Its registry reports affected participants in several retatrutide groups and in placebo. The table presents the two pain terms separately.
Can the two pain categories be added together?
Not as a unique-person total. The public term-level table does not show participant overlap.
Does this study establish how to manage stomach pain?
The event table records reports; it does not compare a home-management intervention or provide a verified symptom-resolution timeline.
The cited research does not establish a personalized prediction, a proven symptom timeline or a home management protocol for the concern in this article. Physician supervision does not turn an investigational substance into an FDA-approved treatment. Participants should report adverse events to their study team rather than infer a dosing change from an article.